Edition:
United Kingdom

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

5,589.00GBp
20 Jul 2018
Change (% chg)

-20.00 (-0.36%)
Prev Close
5,609.00
Open
5,613.00
Day's High
5,642.00
Day's Low
5,540.00
Volume
1,375,180
Avg. Vol
1,939,222
52-wk High
5,665.37
52-wk Low
4,260.00

Latest Key Developments (Source: Significant Developments)

AstraZeneca Says Imfinzi Approved In Japan For Stage III nsclc
Monday, 2 Jul 2018 

July 2 (Reuters) - AstraZeneca PLC ::IMFINZI APPROVED IN JAPAN FOR STAGE III NSCLC.IMFINZI APPROVAL IS BASED ON PHASE III PACIFIC TRIAL.  Full Article

AstraZeneca Says Lynparza Approved In Japan For Brcam Breast Cancer
Monday, 2 Jul 2018 

July 2 (Reuters) - AstraZeneca PLC ::LYNPARZA APPROVED IN JAPAN FOR BRCAM BREAST CANCER.LYNPARZA GENERALLY WELL TOLERATED WITH MAJORITY OF ADVERSE EVENTS REPORTED AS MILD TO MODERATE.  Full Article

AstraZeneca Completes Agreement For Seroquel With Luye Pharma
Thursday, 28 Jun 2018 

June 28 (Reuters) - AstraZeneca PLC ::AZ AND LUYE PHARMA COMPLETE AGREEMENT FOR SEROQUEL.AZ AND LUYE PHARMA COMPLETE AGREEMENT FOR SEROQUEL.ASTRAZENECA HAS RECEIVED A PAYMENT OF $260M FROM LUYE PHARMA AS PART OF TOTAL $538M CONSIDERATION.PAYMENTS OF $240M AND $38M ARE DUE IN DECEMBER 2019 AND JULY 2020, RESPECTIVELY.UNDER TERMS OF AGREEMENT, ASTRAZENECA HAS RECEIVED A PAYMENT OF $260M FROM LUYE PHARMA AS PART OF TOTAL $538M CONSIDERATION.MILESTONE PAYMENT IS ALSO DUE ON SUCCESSFUL TRANSITION OF CERTAIN ACTIVITIES TO LUYE PHARMA.PRESENT VALUE OF UPFRONT AND FUTURE PAYMENTS WILL BE REPORTED AS OTHER OPERATING INCOME IN CO'S FINANCIAL STATEMENTS IN Q2 OF 2018.  Full Article

Astrazeneca Says Lokelma Approved In U.S. For The Treatment Of Adults With Hyperkalaemia
Monday, 21 May 2018 

May 21 (Reuters) - AstraZeneca PLC ::LOKELMA PROVIDES RAPID AND SUSTAINED POTASSIUM CONTROL FOR PATIENTS IN A CONDITION WITH HIGH UNMET NEED.US FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED LOKELMA (SODIUM ZIRCONIUM CYCLOSILICATE), FORMERLY ZS-9, FOR TREATMENT OF ADULTS WITH HYPERKALAEMIA,1.  Full Article

Astrazeneca CEO Says In Ongoing Discussions With Investors On Bonuses
Friday, 18 May 2018 

May 18 (Reuters) - AstraZeneca PLC CEO Pascal Soriot tells reporters::CEO SAYS IN ONGOING DISCUSSIONS WITH INVESTORS TO ADDRESS CONCERNS ON EXECUTIVE BONUS SCHEME.  Full Article

AstraZeneca Says Galathea Phase III Trial Did Not Meet Primary Endpoint
Friday, 11 May 2018 

May 11 (Reuters) - AstraZeneca PLC ::ASTRAZENECA UPDATE ON FASENRA PIII TRIAL IN COPD.GALATHEA PHASE III TRIAL DID NOT MEET PRIMARY ENDPOINT OF A STATISTICALLY-SIGNIFICANT REDUCTION OF EXACERBATIONS IN PATIENTS WITH COPD.SECOND PHASE III TRIAL TERRANOVA IS ONGOING WITH RESULTS EXPECTED LATER THIS QUARTER.SAFETY AND TOLERABILITY FINDINGS IN GALATHEA WERE CONSISTENT WITH THOSE OBSERVED IN PREVIOUS TRIALS WITH FASENRA.RESULTS OF GALATHEA TRIAL DO NOT IMPACT APPROVED INDICATION IN SEVERE EOSINOPHILIC ASTHMA.GALATHEA PHASE III TRIAL DID NOT MEET PRIMARY ENDPOINT OF A STATISTICALLY-SIGNIFICANT REDUCTION OF EXACERBATIONS IN PATIENTS WITH COPD.  Full Article

AstraZeneca Says Lynparza Tablets Receive EU Approval
Tuesday, 8 May 2018 

May 8 (Reuters) - AstraZeneca PLC ::EMA APPROVES LYNPARZA: MAINTENANCE OVARIAN CANCER.LYNPARZA TABLETS RECEIVE EU APPROVAL FOR TREATMENT OF PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER.  Full Article

Luye Pharma Group Acquires Astrazeneca's Rights Relating To Seroquel And Seroquel XR
Monday, 7 May 2018 

May 7 (Reuters) - Luye Pharma Group Ltd <2186.HK>::ANNOUNCES ACQUISITION OF ASTRAZENECA'S RIGHTS RELATING TO SEROQUEL AND SEROQUEL XR IN CHINA AND IN OTHER TERRITORIES.PURCHASE PRICE FOR TRANSFERRED ASSETS AND LICENSED ASSETS IS IN AGGREGATE SUM OF US$546 MILLION.ASTRAZENECA TO TRANSFER ASSETS & GRANT A LICENCE FOR ASSETS TO UNIT IN TERRITORIES INCLUDING CHINA, BRAZIL, AMONG OTHERS.  Full Article

Redx Pharma Appoints Astrazeneca Executive Lisa Anson As CEO
Tuesday, 24 Apr 2018 

April 24 (Reuters) - Redx Pharma PLC ::REDX PHARMA PLC - REDX APPOINTS SENIOR ASTRAZENECA EXECUTIVE AS CEO.REDX PHARMA PLC - APPOINTED LISA ANSON AS CHIEF EXECUTIVE OFFICER (CEO) AND TO ITS BOARD OF DIRECTORS.  Full Article

Ionis And AstraZeneca Advance New Drug For NASH
Monday, 9 Apr 2018 

April 9 (Reuters) - Ionis Pharmaceuticals Inc ::IONIS AND ASTRAZENECA ADVANCE NEW DRUG FOR NASH.IONIS PHARMACEUTICALS INC - EARNS $30 MLN LICENSE FEE FOR IONIS-AZ6-2.5-L RX.IONIS PHARMACEUTICALS INC - ASTRAZENECA WILL BE RESPONSIBLE FOR FURTHER DEVELOPMENT & COMMERCIALIZATION OF IONIS-AZ6-2.5-LRX.IONIS PHARMACEUTICALS INC - AS IONIS-AZ6-2.5-LRX ADVANCES, CO MAY RECEIVE UP TO $300 MLN IN ADDITIONAL DEVELOPMENT & REGULATORY MILESTONE PAYMENTS.  Full Article

Photo

EU drug regulators step up work to prepare for 'no deal' Brexit

LONDON Drug regulators across Europe are hiring extra staff and increasing their workload as the role of British experts in the EU-wide system of medicines supervision winds down ahead of Brexit.